Advances in G Protein-Coupled Receptor Allostery: From Function to Structure
暂无分享,去创建一个
[1] Arthur Christopoulos,et al. Biased Agonism at G Protein‐Coupled Receptors: The Promise and the Challenges—A Medicinal Chemistry Perspective , 2014, Medicinal research reviews.
[2] Arthur Christopoulos,et al. Allosteric targeting of receptor tyrosine kinases , 2014, Nature Biotechnology.
[3] J. Changeux,et al. International Union of Basic and Clinical Pharmacology. XC. Multisite Pharmacology: Recommendations for the Nomenclature of Receptor Allosterism and Allosteric Ligands , 2014, Pharmacological Reviews.
[4] Lynn R. Webster,et al. Biased agonism of the μ-opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: A randomized, double-blind, placebo-controlled, crossover study in healthy volunteers , 2014, PAIN®.
[5] Vadim Cherezov,et al. Structural basis for Smoothened receptor modulation and chemoresistance to anticancer drugs , 2014, Nature Communications.
[6] P. Sexton,et al. A new mechanism of allostery in a G protein-coupled receptor dimer , 2014, Nature chemical biology.
[7] Arthur Christopoulos,et al. Muscarinic acetylcholine receptors: novel opportunities for drug development , 2014, Nature Reviews Drug Discovery.
[8] J. Violin,et al. Biased ligands at G-protein-coupled receptors: promise and progress. , 2014, Trends in pharmacological sciences.
[9] Sarah L. Huszar,et al. Mechanism based neurotoxicity of mGlu5 positive allosteric modulators – Development challenges for a promising novel antipsychotic target , 2014, Neuropharmacology.
[10] A. Christopoulos,et al. Structure-activity relationships of privileged structures lead to the discovery of novel biased ligands at the dopamine D₂ receptor. , 2014, Journal of medicinal chemistry.
[11] Vadim Cherezov,et al. Allosteric sodium in class A GPCR signaling. , 2014, Trends in biochemical sciences.
[12] Travis S. Hughes,et al. An alternate binding site for PPARγ ligands , 2014, Nature Communications.
[13] Jens Meiler,et al. Structure of a Class C GPCR Metabotropic Glutamate Receptor 1 Bound to an Allosteric Modulator , 2014, Science.
[14] Arthur Christopoulos,et al. Functional and structural perspectives on allosteric modulation of GPCRs. , 2014, Current opinion in cell biology.
[15] Martin J. Lohse,et al. G Protein–Coupled Receptor Oligomerization Revisited: Functional and Pharmacological Perspectives , 2014, Pharmacological Reviews.
[16] Joanne Baltos,et al. Separation of on-target efficacy from adverse effects through rational design of a bitopic adenosine receptor agonist , 2014, Proceedings of the National Academy of Sciences.
[17] Arthur Christopoulos,et al. Quantification of Ligand Bias for Clinically Relevant β2-Adrenergic Receptor Ligands: Implications for Drug Taxonomy , 2014, Molecular Pharmacology.
[18] Bryan L. Roth,et al. Molecular control of δ-opioid receptor signalling , 2014, Nature.
[19] Arthur Christopoulos,et al. Molecular Determinants of Allosteric Modulation at the M1 Muscarinic Acetylcholine Receptor* , 2014, The Journal of Biological Chemistry.
[20] Cody J. Wenthur,et al. Drugs for allosteric sites on receptors. , 2014, Annual review of pharmacology and toxicology.
[21] P. Piazza,et al. Pregnenolone Can Protect the Brain from Cannabis Intoxication , 2014, Science.
[22] J. Changeux. 50 years of allosteric interactions: the twists and turns of the models , 2013, Nature Reviews Molecular Cell Biology.
[23] J. Wess,et al. Activation and allosteric modulation of a muscarinic acetylcholine receptor , 2013, Nature.
[24] Albert C. Pan,et al. Structural basis for modulation of a G-protein-coupled receptor by allosteric drugs , 2013, Nature.
[25] A. Christopoulos,et al. A structure-activity analysis of biased agonism at the dopamine D2 receptor. , 2013, Journal of medicinal chemistry.
[26] P. Sexton,et al. Probing structural requirements of positive allosteric modulators of the M4 muscarinic receptor. , 2013, Journal of medicinal chemistry.
[27] Hualiang Jiang,et al. Structure of the CCR5 Chemokine Receptor–HIV Entry Inhibitor Maraviroc Complex , 2013, Science.
[28] Shane M. Devine,et al. Reverse Engineering of the Selective Agonist TBPB Unveils Both Orthosteric and Allosteric Modes of Action at the M1 Muscarinic Acetylcholine Receptor , 2013, Molecular Pharmacology.
[29] Arthur Christopoulos,et al. Emerging paradigms in GPCR allostery: implications for drug discovery , 2013, Nature Reviews Drug Discovery.
[30] Ali Jazayeri,et al. Structure of class B GPCR corticotropin-releasing factor receptor 1 , 2013, Nature.
[31] Shailesh N Mistry,et al. Synthesis and pharmacological profiling of analogues of benzyl quinolone carboxylic acid (BQCA) as allosteric modulators of the M1 muscarinic receptor. , 2013, Journal of medicinal chemistry.
[32] D. Riccardi,et al. The extracellular calcium-sensing receptor, CaSR, in fetal development. , 2013, Best practice & research. Clinical endocrinology & metabolism.
[33] Jie Zhang,et al. Inhibition of tumor angiogenesis and growth by a small-molecule multi-FGF receptor blocker with allosteric properties. , 2013, Cancer cell.
[34] R. Nussinov,et al. Allostery in Disease and in Drug Discovery , 2013, Cell.
[35] Arthur Christopoulos,et al. Signalling bias in new drug discovery: detection, quantification and therapeutic impact , 2012, Nature Reviews Drug Discovery.
[36] P. Sexton,et al. Allosteric Modulation of a Chemogenetically Modified G Protein-Coupled Receptor , 2013, Molecular Pharmacology.
[37] P. Sexton,et al. Impact of clinically relevant mutations on the pharmacoregulation and signaling bias of the calcium-sensing receptor by positive and negative allosteric modulators. , 2013, Endocrinology.
[38] Ulrike Holzgrabe,et al. Molecular alliance-from orthosteric and allosteric ligands to dualsteric/bitopic agonists at G protein coupled receptors. , 2013, Angewandte Chemie.
[39] Arthur Christopoulos,et al. Bridging the gap: bitopic ligands of G-protein-coupled receptors. , 2013, Trends in pharmacological sciences.
[40] R. N. Takahashi,et al. Anti-inflammatory lipoxin A4 is an endogenous allosteric enhancer of CB1 cannabinoid receptor , 2012, Proceedings of the National Academy of Sciences.
[41] Andrew S. Felts,et al. Investigating Metabotropic Glutamate Receptor 5 Allosteric Modulator Cooperativity, Affinity, and Agonism: Enriching Structure-Function Studies and Structure-Activity Relationships , 2012, Molecular Pharmacology.
[42] B. Lutz,et al. Identification and Quantification of a New Family of Peptide Endocannabinoids (Pepcans) Showing Negative Allosteric Modulation at CB1 Receptors* , 2012, The Journal of Biological Chemistry.
[43] U. Holzgrabe,et al. The allosteric vestibule of a seven transmembrane helical receptor controls G-protein coupling , 2012, Nature Communications.
[44] P. Sexton,et al. Allosteric Modulation of Endogenous Metabolites as an Avenue for Drug Discovery , 2012, Molecular Pharmacology.
[45] Where have all the active receptor states gone? , 2012, Nature chemical biology.
[46] R. Stevens,et al. Structural Basis for Allosteric Regulation of GPCRs by Sodium Ions , 2012, Science.
[47] Jean Martinez,et al. Ligands and signaling proteins govern the conformational landscape explored by a G protein-coupled receptor , 2012, Proceedings of the National Academy of Sciences.
[48] Arthur Christopoulos,et al. A simple method for quantifying functional selectivity and agonist bias. , 2012, ACS chemical neuroscience.
[49] P. Sexton,et al. Positive and negative allosteric modulators promote biased signaling at the calcium-sensing receptor. , 2012, Endocrinology.
[50] Bruce J. Melancon,et al. Allosteric modulation of seven transmembrane spanning receptors: theory, practice, and opportunities for central nervous system drug discovery. , 2012, Journal of medicinal chemistry.
[51] Shane M. Devine,et al. Synthesis and characterization of novel 2-amino-3-benzoylthiophene derivatives as biased allosteric agonists and modulators of the adenosine A(1) receptor. , 2012, Journal of medicinal chemistry.
[52] K. Ahn,et al. Allosteric Modulator ORG27569 Induces CB1 Cannabinoid Receptor High Affinity Agonist Binding State, Receptor Internalization, and Gi Protein-independent ERK1/2 Kinase Activation* , 2012, The Journal of Biological Chemistry.
[53] P. Sexton,et al. The best of both worlds? Bitopic orthosteric/allosteric ligands of g protein-coupled receptors. , 2012, Annual review of pharmacology and toxicology.
[54] R. Lefkowitz,et al. Molecular mechanism of β-arrestin-biased agonism at seven-transmembrane receptors. , 2012, Annual review of pharmacology and toxicology.
[55] Malorye Allison,et al. Reinventing clinical trials , 2012, Nature Biotechnology.
[56] L. Miller,et al. Differential sensitivity of types 1 and 2 cholecystokinin receptors to membrane cholesterol , 2012, Journal of Lipid Research.
[57] P. Sexton,et al. Probe Dependence in the Allosteric Modulation of a G Protein-Coupled Receptor: Implications for Detection and Validation of Allosteric Ligand Effects , 2012, Molecular Pharmacology.
[58] A. Kruse,et al. Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist , 2011, Nature.
[59] Arthur Christopoulos,et al. Structure-function studies of muscarinic acetylcholine receptors. , 2012, Handbook of experimental pharmacology.
[60] P. Sexton,et al. Second Extracellular Loop of Human Glucagon-like Peptide-1 Receptor (GLP-1R) Differentially Regulates Orthosteric but Not Allosteric Agonist Binding and Function* , 2011, The Journal of Biological Chemistry.
[61] P. Sexton,et al. Allostery in GPCRs: 'MWC' revisited. , 2011, Trends in biochemical sciences.
[62] P. Sexton,et al. A Monod-Wyman-Changeux Mechanism Can Explain G Protein-coupled Receptor (GPCR) Allosteric Modulation* , 2011, The Journal of Biological Chemistry.
[63] Sudarshan Rajagopal,et al. Quantifying Ligand Bias at Seven-Transmembrane Receptors , 2011, Molecular Pharmacology.
[64] S. Rasmussen,et al. Crystal Structure of the β2Adrenergic Receptor-Gs protein complex , 2011, Nature.
[65] A. Christopoulos,et al. Ligand functional selectivity and quantitative pharmacology at G protein-coupled receptors , 2011, Expert opinion on drug discovery.
[66] C. Langmead,et al. Quantitative Analysis Reveals Multiple Mechanisms of Allosteric Modulation of the mGlu5 Receptor in Rat Astroglia , 2011, Molecular Pharmacology.
[67] P. Sexton,et al. Impact of species variability and ‘probe‐dependence’ on the detection and in vivo validation of allosteric modulation at the M4 muscarinic acetylcholine receptor , 2011, British journal of pharmacology.
[68] Elodie Marcon,et al. Pharmacological characterization of zinc and copper interaction with the human alpha(1A)-adrenoceptor. , 2011, European journal of pharmacology.
[69] A. Christopoulos,et al. Allosteric modulation of the calcium-sensing receptor by gamma-glutamyl peptides: inhibition of PTH secretion, suppression of intracellular cAMP levels, and a common mechanism of action with L-amino acids. , 2011, The Journal of biological chemistry.
[70] P. Gmeiner,et al. Highly potent 5-aminotetrahydropyrazolopyridines: enantioselective dopamine D3 receptor binding, functional selectivity, and analysis of receptor-ligand interactions. , 2011, Journal of medicinal chemistry.
[71] P. Gmeiner,et al. Histidine 6.55 Is a Major Determinant of Ligand-Biased Signaling in Dopamine D2L Receptor , 2011, Molecular Pharmacology.
[72] A. Christopoulos,et al. Quantification of Functional Selectivity at the Human α1A-Adrenoceptor , 2011, Molecular Pharmacology.
[73] P. Sexton,et al. Allosteric modulation of G protein-coupled receptors: A pharmacological perspective , 2011, Neuropharmacology.
[74] S. Pechhold,et al. The extracellular calcium-sensing receptor is required for cholecystokinin secretion in response to L-phenylalanine in acutely isolated intestinal I cells. , 2011, American journal of physiology. Gastrointestinal and liver physiology.
[75] Cheng Zhang,et al. Structure and Function of an Irreversible Agonist-β2 Adrenoceptor complex , 2010, Nature.
[76] C. Boularan,et al. Meningococcus Hijacks a β2-Adrenoceptor/β-Arrestin Pathway to Cross Brain Microvasculature Endothelium , 2010, Cell.
[77] Graeme Milligan,et al. Allostery at G Protein-Coupled Receptor Homo- and Heteromers: Uncharted Pharmacological Landscapes , 2010, Pharmacological Reviews.
[78] Francesca Zazzeroni,et al. The Tetrahydroisoquinoline Derivative SB269,652 Is an Allosteric Antagonist at Dopamine D3 and D2 Receptors , 2010, Molecular Pharmacology.
[79] M. Jacobson,et al. The M1 Muscarinic Receptor Allosteric Agonists AC-42 and 1-[1′-(2-Methylbenzyl)-1,4′-bipiperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one Bind to a Unique Site Distinct from the Acetylcholine Orthosteric Site , 2010, Molecular Pharmacology.
[80] A. Conigrave,et al. Broad-spectrum amino acid-sensing class C G-protein coupled receptors: molecular mechanisms, physiological significance and options for drug development. , 2010, Pharmacology & therapeutics.
[81] P. Sexton,et al. Allosteric Ligands of the Glucagon-Like Peptide 1 Receptor (GLP-1R) Differentially Modulate Endogenous and Exogenous Peptide Responses in a Pathway-Selective Manner: Implications for Drug Screening , 2010, Molecular Pharmacology.
[82] P. White,et al. Delineating the Mode of Action of Adenosine A1 Receptor Allosteric Modulators , 2010, Molecular Pharmacology.
[83] R. Dingledine,et al. Glutamate Receptor Ion Channels: Structure, Regulation, and Function , 2010, Pharmacological Reviews.
[84] P. Sexton,et al. Prediction of Functionally Selective Allosteric Interactions at an M3 Muscarinic Acetylcholine Receptor Mutant Using Saccharomyces cerevisiae , 2010, Molecular Pharmacology.
[85] Arthur Christopoulos,et al. Orthosteric and Allosteric Modes of Interaction of Novel Selective Agonists of the M1 Muscarinic Acetylcholine Receptor , 2010, Molecular Pharmacology.
[86] D. Devost,et al. A Novel Biased Allosteric Compound Inhibitor of Parturition Selectively Impedes the Prostaglandin F2α-mediated Rho/ROCK Signaling Pathway* , 2010, The Journal of Biological Chemistry.
[87] Laurence J. Miller,et al. Seven Transmembrane Receptors as Shapeshifting Proteins: The Impact of Allosteric Modulation and Functional Selectivity on New Drug Discovery , 2010, Pharmacological Reviews.
[88] P. Sexton,et al. Structural Determinants of Allosteric Agonism and Modulation at the M4 Muscarinic Acetylcholine Receptor , 2010, The Journal of Biological Chemistry.
[89] Judy Lin,et al. Hybrid ortho/allosteric ligands for the adenosine A(1) receptor. , 2010, Journal of medicinal chemistry.
[90] U. Holzgrabe,et al. Rational design of dualsteric GPCR ligands: quests and promise , 2010, British journal of pharmacology.
[91] P. Sexton,et al. Molecular Mechanisms of Action and In Vivo Validation of an M4 Muscarinic Acetylcholine Receptor Allosteric Modulator with Potential Antipsychotic Properties , 2010, Neuropsychopharmacology.
[92] Arthur Christopoulos,et al. Identification of Orthosteric and Allosteric Site Mutations in M2 Muscarinic Acetylcholine Receptors That Contribute to Ligand-selective Signaling Bias* , 2010, The Journal of Biological Chemistry.
[93] K. Gregory,et al. Overview of receptor allosterism. , 2000, Current protocols in pharmacology.
[94] M. Millan,et al. The Tetrahydroisoquinoline Derivative SB 269 , 652 Is an Allosteric Antagonist at Dopamine D 3 and D 2 Receptors , 2010 .
[95] A. Chattopadhyay,et al. Membrane cholesterol depletion enhances ligand binding function of human serotonin1A receptors in neuronal cells. , 2009, Biochemical and biophysical research communications.
[96] M. Quirk,et al. A Selective Allosteric Potentiator of the M1 Muscarinic Acetylcholine Receptor Increases Activity of Medial Prefrontal Cortical Neurons and Restores Impairments in Reversal Learning , 2009, The Journal of Neuroscience.
[97] Craig W. Lindsley,et al. Selective activation of the M1 muscarinic acetylcholine receptor achieved by allosteric potentiation , 2009, Proceedings of the National Academy of Sciences.
[98] Antoine Taly,et al. Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system , 2009, Nature Reviews Drug Discovery.
[99] Evi Kostenis,et al. An optical dynamic mass redistribution assay reveals biased signaling of dualsteric GPCR activators , 2009, Journal of receptor and signal transduction research.
[100] Arthur Christopoulos,et al. Allosteric modulators of the adenosine A1 receptor: synthesis and pharmacological evaluation of 4-substituted 2-amino-3-benzoylthiophenes. , 2009, Journal of medicinal chemistry.
[101] Arthur Christopoulos,et al. Orthosteric/allosteric bitopic ligands: going hybrid at GPCRs. , 2009, Molecular interventions.
[102] W. Zuercher,et al. Evidence for Allosteric Interactions of Antagonist Binding to the Smoothened Receptor , 2009, Journal of Pharmacology and Experimental Therapeutics.
[103] C. Lindsley,et al. Discovery and Characterization of Novel Allosteric Potentiators of M1 Muscarinic Receptors Reveals Multiple Modes of Activity , 2009, Molecular Pharmacology.
[104] U. Holzgrabe,et al. Dualsteric GPCR targeting: a novel route to binding and signaling pathway selectivity , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[105] F. Ehlert,et al. Selectivity of Agonists for the Active State of M1 to M4 Muscarinic Receptor Subtypes , 2009, Journal of Pharmacology and Experimental Therapeutics.
[106] Arthur Christopoulos,et al. Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders , 2009, Nature Reviews Drug Discovery.
[107] Arthur Christopoulos,et al. A Novel Mechanism of G Protein-coupled Receptor Functional Selectivity , 2008, Journal of Biological Chemistry.
[108] Aron W Fenton,et al. Allostery: an illustrated definition for the 'second secret of life'. , 2008, Trends in biochemical sciences.
[109] A. Christopoulos,et al. Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia , 2008, Proceedings of the National Academy of Sciences.
[110] M. Whittington,et al. Characterization of a CNS penetrant, selective M1 muscarinic receptor agonist, 77‐LH‐28‐1 , 2008, British journal of pharmacology.
[111] Vadim Cherezov,et al. A specific cholesterol binding site is established by the 2.8 A structure of the human beta2-adrenergic receptor. , 2008, Structure.
[112] H. Schiöth,et al. Structural diversity of G protein-coupled receptors and significance for drug discovery , 2008, Nature Reviews Drug Discovery.
[113] M. Thompson,et al. G protein-coupled receptors disrupted in human genetic disease. , 2008, Methods in molecular biology.
[114] R. Stevens,et al. High-Resolution Crystal Structure of an Engineered Human β2-Adrenergic G Protein–Coupled Receptor , 2007, Science.
[115] Brian K. Kobilka,et al. High resolution crystal structure of human B2-adrenergic G protein-coupled receptor. , 2007 .
[116] Phuong Nguyen,et al. A surface on the androgen receptor that allosterically regulates coactivator binding , 2007, Proceedings of the National Academy of Sciences.
[117] P. Sexton,et al. Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology. , 2007, Trends in pharmacological sciences.
[118] M. Mammen,et al. A Novel Multivalent Ligand That Bridges the Allosteric and Orthosteric Binding Sites of the M2 Muscarinic Receptor , 2007, Molecular Pharmacology.
[119] J. Galzi,et al. A novel, conformation‐specific allosteric inhibitor of the tachykinin NK2 receptor (NK2R) with functionally selective properties , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[120] A. Fryer,et al. Atropine pretreatment enhances airway hyperreactivity in antigen-challenged guinea pigs through an eosinophil-dependent mechanism. , 2007, American journal of physiology. Lung cellular and molecular physiology.
[121] T. Fujita,et al. An acquired hypocalciuric hypercalcemia autoantibody induces allosteric transition among active human Ca-sensing receptor conformations , 2007, Proceedings of the National Academy of Sciences.
[122] W. Catterall,et al. Voltage-gated ion channels and gating modifier toxins. , 2007, Toxicon : official journal of the International Society on Toxinology.
[123] Arthur Christopoulos,et al. Functional Selectivity and Classical Concepts of Quantitative Pharmacology , 2007, Journal of Pharmacology and Experimental Therapeutics.
[124] John P. Overington,et al. How many drug targets are there? , 2006, Nature Reviews Drug Discovery.
[125] C. Langmead,et al. Allosteric agonists of 7TM receptors: expanding the pharmacological toolbox. , 2006, Trends in pharmacological sciences.
[126] U. Holzgrabe,et al. Design, synthesis, and action of oxotremorine-related hybrid-type allosteric modulators of muscarinic acetylcholine receptors. , 2006, Journal of medicinal chemistry.
[127] P. Sexton,et al. GPCR modulation by RAMPs. , 2006, Pharmacology & therapeutics.
[128] P. Conn,et al. A Selective Allosteric Potentiator of Metabotropic Glutamate (mGlu) 2 Receptors Has Effects Similar to an Orthosteric mGlu2/3 Receptor Agonist in Mouse Models Predictive of Antipsychotic Activity , 2005, Journal of Pharmacology and Experimental Therapeutics.
[129] P. Conn,et al. Allosteric Potentiators of Metabotropic Glutamate Receptor Subtype 5 Have Differential Effects on Different Signaling Pathways in Cortical Astrocytes , 2005, Journal of Pharmacology and Experimental Therapeutics.
[130] T. Kenakin. New Concepts in Drug Discovery: Collateral Efficacy and Permissive Antagonism , 2005, Nature Reviews Drug Discovery.
[131] F. Ehlert. Analysis of Allosterism in Functional Assays , 2005, Journal of Pharmacology and Experimental Therapeutics.
[132] A. Christopoulos,et al. Allosteric Modulation of the Cannabinoid CB1 Receptor , 2005, Molecular Pharmacology.
[133] J. Geibel,et al. L-type amino acids stimulate gastric acid secretion by activation of the calcium-sensing receptor in parietal cells. , 2005, American journal of physiology. Gastrointestinal and liver physiology.
[134] J. M. Mathiesen,et al. Identification of Indole Derivatives Exclusively Interfering with a G Protein-Independent Signaling Pathway of the Prostaglandin D2 Receptor CRTH2 , 2005, Molecular Pharmacology.
[135] R. Olsen,et al. Fishing for allosteric sites on GABA(A) receptors. , 2004, Biochemical pharmacology.
[136] F. Locatelli,et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. , 2004, The New England journal of medicine.
[137] B. Roth,et al. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia , 2004, Nature Reviews Drug Discovery.
[138] D. Kendall,et al. Oleamide is a selective endogenous agonist of rat and human CB1 cannabinoid receptors , 2004, British journal of pharmacology.
[139] E. Borda,et al. Circulating antibodies against neonatal cardiac muscarinic acetylcholine receptor in patients with Sjögren's syndrome , 1996, Molecular and Cellular Biochemistry.
[140] S. Lazareno,et al. Thiochrome enhances acetylcholine affinity at muscarinic M4 receptors: receptor subtype selectivity via cooperativity rather than affinity. , 2004, Molecular pharmacology.
[141] Arthur Christopoulos,et al. International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on Terms and Symbols in Quantitative Pharmacology , 2003, Pharmacological Reviews.
[142] F. Wieland,et al. Glutamate-binding affinity of Drosophila metabotropic glutamate receptor is modulated by association with lipid rafts , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[143] D. Kerr,et al. Potentiation of metabotropic GABAB receptors by L-amino acids and dipeptides in rat neocortex. , 2003, European journal of pharmacology.
[144] P. Sexton,et al. Novel Receptor Partners and Function of Receptor Activity-modifying Proteins* , 2003, The Journal of Biological Chemistry.
[145] B. Kobilka,et al. Identification of an Allosteric Binding Site for Zn2+on the β2 Adrenergic Receptor* , 2003, The Journal of Biological Chemistry.
[146] A. C. C. Carvalho,et al. H uman chagasic IgGs bind to cardiac muscarinic receptors and impair 2 1 L-type Ca currents , 2003 .
[147] T. Schwartz,et al. Metal Ion-mediated Agonism and Agonist Enhancement in Melanocortin MC1 and MC4 Receptors* , 2002, The Journal of Biological Chemistry.
[148] U. Hacksell,et al. Discovery of an ectopic activation site on the M(1) muscarinic receptor. , 2002, Molecular pharmacology.
[149] T. Kenakin,et al. G Protein-Coupled Receptor Allosterism and Complexing , 2002, Pharmacological Reviews.
[150] A. Christopoulos. Allosteric binding sites on cell-surface receptors: novel targets for drug discovery , 2002, Nature Reviews Drug Discovery.
[151] B. Kobilka,et al. Allosteric Modulation of β2-Adrenergic Receptor by Zn2+ , 2002 .
[152] Willem Soudijn,et al. Allosteric modulation of G-protein-coupled receptors , 2001 .
[153] D. Sibley,et al. The binding-site crevice of the D4 dopamine receptor is coupled to three distinct sites of allosteric modulation. , 2001, The Journal of pharmacology and experimental therapeutics.
[154] A. Christopoulos. Overview of Receptor Allosterism , 2000 .
[155] E. Brown,et al. L-amino acid sensing by the extracellular Ca2+-sensing receptor. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[156] L. Prézeau,et al. Ca(2+) requirement for high-affinity gamma-aminobutyric acid (GABA) binding at GABA(B) receptors: involvement of serine 269 of the GABA(B)R1 subunit. , 2000, Molecular pharmacology.
[157] P B Hedlund,et al. Allosteric regulation by oleamide of the binding properties of 5-hydroxytryptamine7 receptors. , 1999, Biochemical pharmacology.
[158] F. Gasparini,et al. SIB-1757 and SIB-1893: selective, noncompetitive antagonists of metabotropic glutamate receptor type 5. , 1999, The Journal of pharmacology and experimental therapeutics.
[159] M Morfis,et al. Multiple amylin receptors arise from receptor activity-modifying protein interaction with the calcitonin receptor gene product. , 1999, Molecular pharmacology.
[160] F. Gasparini,et al. CPCCOEt, a noncompetitive metabotropic glutamate receptor 1 antagonist, inhibits receptor signaling without affecting glutamate binding. , 1999, Molecular pharmacology.
[161] E. Borda,et al. Alterations in cardiac beta-adrenergic receptors in chagasic mice and their association with circulating beta-adrenoceptor-related autoantibodies. , 1999, Cardiovascular research.
[162] J. Sutcliffe,et al. Oleamide‐induced Modulation of 5‐Hydroxytryptamine Receptor‐mediated Signaling a , 1998, Annals of the New York Academy of Sciences.
[163] D. Colquhoun,et al. Binding, gating, affinity and efficacy: The interpretation of structure‐activity relationships for agonists and of the effects of mutating receptors , 1998, British journal of pharmacology.
[164] U. Holzgrabe,et al. Identification of a [3H]Ligand for the common allosteric site of muscarinic acetylcholine M2 receptors. , 1998, Molecular pharmacology.
[165] Melanie G. Lee,et al. RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor , 1998, Nature.
[166] Hans H. Zingg,et al. Inhibition of oxytocin receptor function by direct binding of progesterone , 1998, Nature.
[167] M. Neal,et al. Unique allosteric regulation of 5-hydroxytryptamine receptor-mediated signal transduction by oleamide. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[168] J L Benovic,et al. Agonist-Receptor-Arrestin, an Alternative Ternary Complex with High Agonist Affinity* , 1997, The Journal of Biological Chemistry.
[169] G. Gimpl,et al. Cholesterol as modulator of receptor function. , 1997, Biochemistry.
[170] E. Borda,et al. Desensitization and Sequestration of Human m2 Muscarinic Acetylcholine Receptors by Autoantibodies from Patients with Chagas’ Disease* , 1997, The Journal of Biological Chemistry.
[171] D. Sibley,et al. Zinc Allosterically Modulates Antagonist Binding to Cloned D1 and D2 Dopamine Receptors , 1997, Journal of neurochemistry.
[172] P. Hedera,et al. Delirium in Alzheimer Disease , 1997, Alzheimer disease and associated disorders.
[173] W W Offen,et al. The selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of Alzheimer disease. , 1997, Alzheimer disease and associated disorders.
[174] R. Hen,et al. 5-hydroxytryptamine-moduline, a new endogenous cerebral peptide, controls the serotonergic activity via its specific interaction with 5-hydroxytryptamine1B/1D receptors. , 1996, Molecular pharmacology.
[175] M. Delepierre,et al. Isolation and Characterization of an Endogenous Peptide from Rat Brain Interacting Specifically with the Serotonergic 1B Receptor Subtypes (*) , 1996, The Journal of Biological Chemistry.
[176] E. Zifa,et al. A new peptide, 5-HT-moduline, isolated and purified from mammalian brain specifically interacts with 5-HT 1B 1D receptors , 1995, Behavioural Brain Research.
[177] M. Spedding,et al. New drug binding sites in Ca2+ channels. , 1995, Trends in pharmacological sciences.
[178] P P Humphrey,et al. International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. , 1994, Pharmacological reviews.
[179] G. Gleich,et al. Human eosinophil major basic protein is an endogenous allosteric antagonist at the inhibitory muscarinic M2 receptor. , 1993, The Journal of clinical investigation.
[180] J. Ellis,et al. Two allosteric modulators interact at a common site on cardiac muscarinic receptors. , 1992, Molecular pharmacology.
[181] J. Traynor,et al. Differential Effects of Mg2+ and Other Divalent Cations on the Binding of Tritiated Opioid Ligands , 1992, Journal of neurochemistry.
[182] J. Fergus,et al. Allosteric enhancement of adenosine A1 receptor binding and function by 2-amino-3-benzoylthiophenes. , 1990, Molecular pharmacology.
[183] M. Spedding,et al. Direct activation of Ca2+ channels by palmitoyl carnitine, a putative endogenous ligand , 1987, British journal of pharmacology.
[184] F. Ehlert. The relationship between muscarinic receptor occupancy and adenylate cyclase inhibition in the rabbit myocardium. , 1985, Molecular pharmacology.
[185] J. Black,et al. Operational models of pharmacological agonism , 1983, Proceedings of the Royal Society of London. Series B. Biological Sciences.
[186] N. Birdsall,et al. Modification of the binding properties of muscarinic receptors by gallamine. , 1983, Molecular pharmacology.
[187] H. Yamamura,et al. Modulation of benzodiazepine receptor binding: insight into pharmacological efficacy. , 1982, European journal of pharmacology.
[188] R. Lefkowitz,et al. A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled beta-adrenergic receptor. , 1980, The Journal of biological chemistry.
[189] P. Krogsgaard‐Larsen,et al. Partial agonists for brain GABA/benzodiazepine receptor complex , 1979, Nature.
[190] R. Lefkowitz,et al. Magnesium dependence of agonist binding to adenylate cyclase-coupled hormone receptors. , 1978, The Journal of biological chemistry.
[191] F. Mitchelson,et al. THE INHIBITORY EFFECT OF GALLAMINE ON MUSCARINIC RECEPTORS , 1976, British journal of pharmacology.
[192] S. Snyder,et al. Selective enhancement of [3H]opiate agonist binding by divalent cations. , 1975, Molecular pharmacology.
[193] E. J. Simon,et al. Kinetics of opiate receptor inactivation by sulfhydryl reagents: evidence for conformational change in presence of sodium ions. , 1975, Proceedings of the National Academy of Sciences of the United States of America.
[194] S. Snyder,et al. Opiate Agonists and Antagonists Discriminated by Receptor Binding in Brain , 1973, Science.
[195] W. Wooster,et al. Crystal structure of , 2005 .
[196] O. Wassermann,et al. Inhibition of the actions of carbachol and DFP on guinea pig isolated atria by alkane-bis-ammonium compounds. , 1969, European journal of pharmacology.
[197] D. Koshland,et al. Comparison of experimental binding data and theoretical models in proteins containing subunits. , 1966, Biochemistry.
[198] J. Changeux,et al. ON THE NATURE OF ALLOSTERIC TRANSITIONS: A PLAUSIBLE MODEL. , 1965, Journal of molecular biology.
[199] J. Changeux,et al. Allosteric proteins and cellular control systems. , 1963, Journal of molecular biology.
[200] H. Kowarzyk. Structure and Function. , 1910, Nature.